1. Trang chủ
  2. » Thể loại khác

Ebook Cardiology in family practice - A practical guide: Part 2

74 108 0

Đang tải... (xem toàn văn)

Tài liệu hạn chế xem trước, để xem đầy đủ mời bạn chọn Tải xuống

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Định dạng
Số trang 74
Dung lượng 4,74 MB

Nội dung

(BQ) Part 2 book “Cardiology in family practice - A practical guide” has contents: Congestive heart failure, hypertension, valvular diseases, pericardial diseases, prevention of bacterial endocarditis, hyperlipidemia.

Chapter Hypertension Etiology and Pathophysiology Hypertension is highly prevalent in the United States and worldwide, and it is a major risk factor for coronary artery disease, stroke, heart failure, renal disease, and cardiovascular events [1] The prevalence of hypertension increases with age The Framingham Heart Study reported a 90% lifetime risk for developing hypertension in patients who are normotensive at the age of 50 [2] The risk of cardiovascular disease doubles with each increment of 20/10 mmHg above 115/75 [3] Systolic hypertension is now considered a more important risk factor than diastolic pressure [4, 5] An estimated 50 million Americans have high blood pressure, but awareness, treatment, and control is still poor, especially in the elderly [6] A national health survey performed from 1988 to 1991 [7], and repeated from 1999 to 2000 found that the prevalence of hypertension has increased from 20 to 27% over the past decade [6] The 1999–2000 survey found that one third of hypertensive patients were not aware of their disease, less than two-thirds adopted lifestyle modification or took medication to lower their blood pressure, and only 31% were at their blood pressure goal [6] It is little consolation that international blood pressure control rates were no better Between 2004 and 2008, there was a (29.4%) reduction in the rate of uncontrolled hypertension, indicating that progress has been made toward the American Heart Association’s (AHA) Impact 2010 goals for CHD and stroke [8] The most recent AHA Impact 2020 goals call for even greater reductions in the prevalence of hypertension along with the other major risk factor for vascular disease (goal untreated BP

Ngày đăng: 21/01/2020, 00:07

Nguồn tham khảo

Tài liệu tham khảo Loại Chi tiết
1. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–96 Khác
2. Wilson PW et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47 Khác
3. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81(4A):7B–12 Khác
4. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta- analysis. Am J Med. 2006;119(10):812–9 Khác
5. Grundy SM et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720–32 Khác
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22 Khác
7. Ridker PM et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207 Khác
8. Shepherd J et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30 Khác
9. ALLHAT Investigators. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998–3007 Khác
10. Sever PS et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58 Khác
11. Cannon CP et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504 Khác
12. Ridker PM et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–8 Khác
13. Fonarow GC et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol.2001;87(7):819–22 Khác
14. LaRosa JC et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–35 Khác
15. Davidson MH et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40(12):2125–34 Khác
16. Kastelein JJ et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431–43 Khác
17. Rossebo AB et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343–56 Khác
18. Peto R et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008; 359(13):1357–66 Khác
19. Harris WS et al. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation. 2009;119(6):902–7 Khác